Emerging Company Profile
VectorY: Forbion’s next-generation gene therapy play
Emerging Company Profile: With €31M, VectorY builds a toolbox to develop, manufacture vectorized antibodies
With €31M, VectorY builds a toolbox to develop and manufacture vectorized antibodies.
Jun 15, 2021 | 9:12 PM GMT
Forbion-backed VectorY is assembling a set of tools and key personnel to create vectorized antibody therapeutics designed